Compared with patients with poor adherence (hazard ratio [HR] = 1), the risk of all-cause death, stroke, or acute myocardial infarction was significantly lower in patients with good (HR = 0.69, P < 0.001) and excellent adherence (HR = 0.53, P < 0.001).
Lymph node KLK6 positivity was an indicator of poor outcome (hazard ratio 3.7).
High MYC expression was also associated with poor survival (hazard ratio = 2.63, 95% CI 1.16 to 5.92; P = 0.02).
RESULTS: MVD was higher across T- and N-stages (P<0.001) and associated with poor survival (Hazard ratio (HR 8.7, P<0.005) and decreased disease-free survival (HR=4.7, P<0.005).
In addition, low Bif-1 expression was found to be the independent indicator of poor prognosis (Hazard ratio, 0.459; 95% CI, 0.285 0.739; P = 0.001; Table 3).
sCXCL16 independently predicted for poor survival (hazard ratio=2.28, 95% confidence interval=1.29 4.02, P=0.005), whereas neither CXCL16 nor CXCR6 expression correlated with survival.
Survival analysis showed that the AKI sepsis group had a poor prognosis (hazard ratio = 0.43, 95% CI 0.202 to 0.924, χ = 4.681, P = 0.031).
Pechet et al 3 concluded that the presence of arterial invasion in stage I NSCLC patients was adversely associated with poor survival (hazard ratio [HR], 3.5) (P < 0.001).
The KLK6 positivity in lymph nodes with few tumour cells, that is, low CEA mRNA levels, also indicated poor prognosis (hazard ratio 2.8).
Microvessel density was higher across T and N stages (P<0.001) and associated with poor survival (hazard ratio (HR)=8.7, P<0.005) and decreased disease-free survival (HR=4.7, P<0.005).
